← Back to front page
United States · Financial press · Investor's Business Daily

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Published by Investor's Business Daily · United States 2 h ago

Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari. The post Travere Is On A Crash Course With…

Read the full article on Investor's Business Daily Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)

Also worth reading

The Wall Street Journal

Stocks Are Mixed After Apple Earnings Disappoint

 Barron's

Midterms, Markets, and Earnings Malaise. Apple and Palantir Sum Up the Mood.